Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.

about

AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.Targeted therapies in breast cancer: New challenges to fight against resistance.

P2860

Q37695410-E65CBEC3-E245-4A3F-9757-C3DD051742EF Q37743048-898B8595-627F-4BAC-8BBA-25A86F7D1448

P2860

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.

Item

http://www.wikidata.org/entity/Q38825945

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.

@en

type

Item

label

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.

@en

prefLabel

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.

@en

P1476

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.

@en

P2093

Erica B Bernhardt

http://www.w3.org/2001/XMLSchema#string

Mary D Chamberlin

http://www.w3.org/2001/XMLSchema#string

Todd W Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Should individual PI3 kinase isoforms be targeted in cancer?

Comprehensive molecular portraits of human breast tumours

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

Activating HER2 mutations in HER2 gene amplification negative breast cancer

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

P304

2454-2463

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1002/JCB.25590

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27146558

http://www.w3.org/2001/XMLSchema#string

P932

6010350

http://www.w3.org/2001/XMLSchema#string

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.

about

P2860

P2860

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932